Targeting the Tumor Microenvironment in Breast Cancer: Prognostic and Predictive Significance and Therapeutic Opportunities

Breast cancer is one of the most prevalent tumors among women. Its prognosis and treatment outcomes depend on factors related to tumor cell biology. However, recent studies have revealed the critical role of the tumor microenvironment (TME) in the development, progression, and treatment response of breast cancer. In this review, we explore the different components of the TME and their relevance as prognostic and predictive biomarkers in breast cancer. In addition, techniques for assessing the tumor microenvironment, such as immunohistochemistry or gene expression profiling, and their clinical utility in therapeutic decision-making are examined. Finally, therapeutic strategies targeting the TME are reviewed, highlighting their potential clinical benefits. Overall, this review emphasizes the importance of the TME in breast cancer and its potential as a clinical tool for better patient stratification and the design of personalized therapies.

Automated summary

Breast cancer prognosis and treatment outcomes depend on tumor microenvironment (TME), which plays a critical role in its development, progression, and treatment response. This review examines the different components of TME as prognostic and predictive biomarkers in breast cancer. Techniques for assessing TME, such as immunohistochemistry or gene expression profiling, and their clinical utility in therapeutic decision-making are also discussed. Lastly, therapeutic strategies targeting TME are reviewed, highlighting their potential clinical benefits.